MX2018003757A - Composiciones y metodos para producir celulas dendriticas. - Google Patents
Composiciones y metodos para producir celulas dendriticas.Info
- Publication number
- MX2018003757A MX2018003757A MX2018003757A MX2018003757A MX2018003757A MX 2018003757 A MX2018003757 A MX 2018003757A MX 2018003757 A MX2018003757 A MX 2018003757A MX 2018003757 A MX2018003757 A MX 2018003757A MX 2018003757 A MX2018003757 A MX 2018003757A
- Authority
- MX
- Mexico
- Prior art keywords
- dendritic cells
- methods
- compositions
- lysis
- cell surface
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000009089 cytolysis Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100001160 nonlethal Toxicity 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
En el presente documento se describen composiciones y métodos para tratar una enfermedad, en particular, un cáncer, con células dendríticas cebadas que reconocen un antígeno tumoral. Los métodos pueden comprender almacenar, transportar y/o cultivar células dendríticas, donde las células dendríticas se almacenan sobre una superficie dura. Se describen protocolos de lisis donde la lisis no da como resultado la lisis completa de las células para proporcionar moléculas de la superficie celular mantenidas en un estado incluido en la superficie celular. También se proporcionan cepas no letales del virus del Dengue con fines terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562284434P | 2015-09-26 | 2015-09-26 | |
PCT/US2016/053554 WO2017053873A1 (en) | 2015-09-26 | 2016-09-23 | Compositions and methods for producing dendritic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003757A true MX2018003757A (es) | 2018-09-21 |
Family
ID=58387383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003757A MX2018003757A (es) | 2015-09-26 | 2016-09-23 | Composiciones y metodos para producir celulas dendriticas. |
Country Status (7)
Country | Link |
---|---|
US (2) | US10765727B2 (es) |
EP (2) | EP3865150A1 (es) |
JP (2) | JP2018535191A (es) |
CN (1) | CN108291205A (es) |
CA (1) | CA2999881A1 (es) |
MX (1) | MX2018003757A (es) |
WO (1) | WO2017053873A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202016008300U1 (de) | 2015-07-02 | 2017-07-14 | PrimeVax Immuno-Oncology, Inc. | Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen |
EP3865150A1 (en) | 2015-09-26 | 2021-08-18 | Primevax Immuno-Oncology, Inc. | Combination therapy with dengue virus and dendritic cells |
JP2020500847A (ja) | 2016-11-16 | 2020-01-16 | プライムヴァックス イミュノ−オンコロジー,インク. | 癌の処置のための併用免疫療法 |
SG11201912163WA (en) * | 2017-06-15 | 2020-01-30 | Primevax Immuno Oncology Inc | Compositions and methods for cancer therapy with dengue virus and dendritic cells |
CN109096386A (zh) * | 2018-08-31 | 2018-12-28 | 上海莱馥生命科学技术有限公司 | 一种乳腺癌干细胞抗原的制备方法和应用 |
CN109609452A (zh) * | 2018-12-27 | 2019-04-12 | 青岛麦迪赛斯生物科技有限公司 | 一种高效的巨噬细胞体外制备方法 |
CN109781977B (zh) * | 2019-01-09 | 2022-03-29 | 首都医科大学附属北京安定医院 | IL15Rα以及相关膜蛋白检测试剂盒及其应用 |
CN116333969A (zh) * | 2023-02-01 | 2023-06-27 | 宁波荣安生物药业有限公司 | 一种狂犬病毒用Vero细胞培养方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
AU2872199A (en) | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
US6524587B1 (en) | 1998-05-05 | 2003-02-25 | Bruce W. Lyday | Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors |
US6048686A (en) | 1998-05-05 | 2000-04-11 | Randy Kyle Brown | Hyperthermia and immunotherapy for cancer |
WO2000057909A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
CN1191092C (zh) | 1999-03-26 | 2005-03-02 | 沃尔特里德军事研究院 | 多价登革病毒疫苗 |
EP1168924A4 (en) | 1999-03-31 | 2002-09-04 | Univ Pittsburgh | DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL |
EP1484064A1 (en) | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
AU2005257105A1 (en) | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing minus-strand RNA virus |
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
CA3004991C (en) | 2006-08-15 | 2022-08-30 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of dengue virus vaccine components |
EP2547360A4 (en) * | 2010-03-15 | 2013-11-20 | Univ Pennsylvania | SYSTEM AND METHOD FOR THE PRODUCTION AND STORAGE OF ACTIVATED TIRES OF DENDRITIC CELLS |
EA201391515A1 (ru) | 2011-05-26 | 2014-05-30 | Глаксосмитклайн Байлоджикалс С.А. | Инактивированная вакцина вируса денге |
US20150125489A1 (en) * | 2012-03-02 | 2015-05-07 | Laboratorios Del Dr. Esteve, S.A. | Method for the preparation of dendritic cell vaccines |
US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
EP2858668A1 (en) | 2012-06-10 | 2015-04-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
WO2016179475A1 (en) | 2015-05-07 | 2016-11-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
DE202016008300U1 (de) | 2015-07-02 | 2017-07-14 | PrimeVax Immuno-Oncology, Inc. | Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen |
EP3865150A1 (en) | 2015-09-26 | 2021-08-18 | Primevax Immuno-Oncology, Inc. | Combination therapy with dengue virus and dendritic cells |
JP2020500847A (ja) | 2016-11-16 | 2020-01-16 | プライムヴァックス イミュノ−オンコロジー,インク. | 癌の処置のための併用免疫療法 |
WO2018129202A1 (en) | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
SG11201912163WA (en) | 2017-06-15 | 2020-01-30 | Primevax Immuno Oncology Inc | Compositions and methods for cancer therapy with dengue virus and dendritic cells |
-
2016
- 2016-09-23 EP EP21154546.2A patent/EP3865150A1/en not_active Withdrawn
- 2016-09-23 CN CN201680069385.4A patent/CN108291205A/zh active Pending
- 2016-09-23 CA CA2999881A patent/CA2999881A1/en active Pending
- 2016-09-23 JP JP2018515605A patent/JP2018535191A/ja not_active Ceased
- 2016-09-23 US US15/275,073 patent/US10765727B2/en active Active
- 2016-09-23 MX MX2018003757A patent/MX2018003757A/es unknown
- 2016-09-23 EP EP16849798.0A patent/EP3353287B1/en active Active
- 2016-09-23 WO PCT/US2016/053554 patent/WO2017053873A1/en active Application Filing
-
2020
- 2020-07-29 US US16/942,058 patent/US20200360497A1/en not_active Abandoned
-
2021
- 2021-09-24 JP JP2021155820A patent/JP2022023061A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017053873A1 (en) | 2017-03-30 |
US10765727B2 (en) | 2020-09-08 |
EP3353287A4 (en) | 2019-05-22 |
EP3865150A1 (en) | 2021-08-18 |
EP3353287B1 (en) | 2022-03-09 |
JP2022023061A (ja) | 2022-02-07 |
JP2018535191A (ja) | 2018-11-29 |
US20170087233A1 (en) | 2017-03-30 |
US20200360497A1 (en) | 2020-11-19 |
EP3353287A1 (en) | 2018-08-01 |
CN108291205A (zh) | 2018-07-17 |
CA2999881A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018003757A (es) | Composiciones y metodos para producir celulas dendriticas. | |
PH12016502505A1 (en) | Bispecific t cell activating antigen binding molecules | |
PH12017500939A1 (en) | T cell activating bispecific antigen binding molecules agiant folr1 and cd1 | |
EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
MX2019015194A (es) | Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas. | |
MY201637A (en) | Natural killer cells and ilc3 cells and uses thereof | |
WO2018064594A3 (en) | Hla class i-deficient nk-92 cells with decreased immunogenicity | |
CO2018006133A2 (es) | Materiales y métodos para el tratamiento de miopatías basadas en titina y otras titinopatías | |
GB2573664A (en) | Viral methods of T cell therapy | |
MX2020005503A (es) | Metodos para activar, modificar y expandir linfocitos t gamma delta para el tratamiento del cancer y de neoplasias malignas relacionadas. | |
EP3988655A3 (en) | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene | |
MX2017006626A (es) | Cadenas ligeras comunes y metodos de uso. | |
MX2020010194A (es) | Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. | |
EP4339287A3 (en) | Modified cells and methods of therapy | |
MX2020009692A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
MX2015010350A (es) | Moleculas de union a antigeno biespecificas que activan la celula t. | |
MX2015010843A (es) | Moleculas biespecificas de union al antigeno que activan celulas t. | |
ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
MX2017008737A (es) | Poblaciones de celulas rpe y metodos para generar las mismas. | |
EP3998341A3 (en) | Adenoviral vectors | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer |